This article is more than 5 years old. Information may no longer be current.
Centrexion Therapeutics announces results from study on injection for relief of OA knee pain
Click Here to Manage Email Alerts
Centrexion Therapeutics announced positive data from its phase 2b study of patients with knee osteoarthritis pain treated with CNTX-4975, the company’s lead pipeline candidate for pain reduction.
According to a company press release, the level 1 TRIMUPH study included 175 patients with moderate to severe osteoarthritis knee pain. Investigators randomized patients to receive either a single, 0.5-mg CNTX-4975 injection into the knee, 1 mg of CNTX-4975 or placebo. Pain with walking after 12 weeks was the study endpoint. Patients were followed for 24 weeks to determine response duration of the injection.
At 12 weeks, both CNTX-4975 doses were significantly more effective compared with placebo regarding pain with walking. The effect of the injection lasted for at least 24 weeks after the single dose, according to the release.
“With these positive data in hand, the recent fast track designation for CNTX-4975 in Morton’s neuroma, and our acquisition of three novel pain treatment programs earlier this year, we are advancing a robust and diverse pipeline of non-opioid, chronic pain therapies that have the potential to bridge the safety and efficacy gaps in current chronic pain management,” Jeffrey B. Kindler, chief executive officer of Centrexion Therapeutics, said in the release.
Reference: